Genentech to restrict Avastin availability due to off-label use

10/11/2007 | Wall Street Journal, The · NYTimes.com

Genentech said it will halt the distribution of its cancer treatment Avastin to compounding pharmacies as more ophthalmologists recommend the drug's off-label use for wet age-related macular degeneration. The move is an attempt to promote Genentech's more-expensive eye drug Lucentis, which has lagged in sales, but Medicare says limiting distribution of the cancer drug could cost the system as much as $3 billion a year.

View Full Article in:

Wall Street Journal, The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC